Mai Capital Management Anavex Life Sciences Corp. Transaction History
Mai Capital Management
- $15.6 Billion
- Q3 2025
A detailed history of Mai Capital Management transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Mai Capital Management holds 310 shares of AVXL stock, worth $1,128. This represents 0.0% of its overall portfolio holdings.
Number of Shares
310Holding current value
$1,128% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding AVXL
# of Institutions
212Shares Held
32.2MCall Options Held
1.82MPut Options Held
1.09M-
Black Rock Inc. New York, NY6.39MShares$23.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.1MShares$18.6 Million0.0% of portfolio
-
State Street Corp Boston, MA3.29MShares$12 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.03MShares$7.38 Million0.0% of portfolio
-
Two Sigma Investments, LP New York, NY1.04MShares$3.77 Million0.02% of portfolio
About ANAVEX LIFE SCIENCES CORP.
- Ticker AVXL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,942,800
- Market Cap $284M
- Description
- Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...